Arcus Biosciences, Inc. (RCUS)
15.62
-0.16
(-1.01%)
USD |
NYSE |
Nov 20, 16:00
15.64
+0.02
(+0.13%)
Pre-Market: 20:00
Arcus Biosciences Enterprise Value : 1.479B for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | 1.479B |
| November 19, 2026 | 1.500B |
| November 18, 2026 | 1.497B |
| November 17, 2026 | 1.577B |
| November 16, 2026 | 1.637B |
| November 13, 2026 | 1.710B |
| November 12, 2026 | 1.753B |
| November 11, 2026 | 1.885B |
| November 10, 2026 | 1.868B |
| November 09, 2026 | 1.904B |
| November 06, 2026 | 1.819B |
| November 05, 2026 | 1.743B |
| November 04, 2026 | 1.950B |
| November 03, 2026 | 1.899B |
| November 02, 2026 | 1.764B |
| October 30, 2026 | 1.807B |
| October 29, 2026 | 1.861B |
| October 28, 2026 | 1.833B |
| October 27, 2026 | 1.801B |
| October 26, 2026 | 1.752B |
| October 23, 2026 | 1.852B |
| October 22, 2026 | 1.956B |
| October 21, 2026 | 1.923B |
| October 20, 2026 | 2.516B |
| October 19, 2026 | 2.311B |
| Date | Value |
|---|---|
| October 16, 2026 | 2.309B |
| October 15, 2026 | 2.398B |
| October 14, 2026 | 2.361B |
| October 13, 2026 | 2.358B |
| October 12, 2026 | 2.592B |
| October 09, 2026 | 2.601B |
| October 08, 2026 | 2.527B |
| October 07, 2026 | 2.615B |
| October 06, 2026 | 2.584B |
| October 05, 2026 | 2.643B |
| October 02, 2026 | 2.605B |
| October 01, 2026 | 2.705B |
| September 30, 2026 | 2.782B |
| September 29, 2026 | 2.670B |
| September 28, 2026 | 2.588B |
| September 25, 2026 | 2.583B |
| September 24, 2026 | 2.595B |
| September 23, 2026 | 2.764B |
| September 22, 2026 | 2.824B |
| September 21, 2026 | 2.708B |
| September 18, 2026 | 2.617B |
| September 17, 2026 | 2.656B |
| September 16, 2026 | 2.543B |
| September 15, 2026 | 2.501B |
| September 14, 2026 | 2.469B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Halozyme Therapeutics, Inc. | 12.58B |
| AVITA Medical, Inc. | 520.27M |
| Iovance Biotherapeutics, Inc. | 2.860B |
| Editas Medicine, Inc. | 132.56M |
| Recursion Pharmaceuticals, Inc. | 892.80M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -128.00M |
| Revenue (Quarterly) | 9.00M |
| Total Expenses (Quarterly) | 137.00M |
| EPS Diluted (Quarterly) | -1.005 |
| Gross Profit Margin (Quarterly) | 77.78% |
| Profit Margin (Quarterly) | -1.42K% |
| Earnings Yield | -23.31% |
| Normalized Earnings Yield | -23.31 |